FAS (CD95) Mutations Are Rare in Gastric MALT Lymphoma but Occur More Frequently in Primary Gastric Diffuse Large B-Cell Lymphoma

American Journal of Pathology

Volumn 164, Issue 3, 2004, Pages 1081-1089

  Wohlfart, Sabine ^a   Sebinger, David ^a   Gruber, Petra ^a   Buch, Judith ^a   Polgar, Doris ^a   Krupitza, Georg ^a   Rosner, Margit ^b   Hengstschläger, Markus ^b   Raderer, Markus ^b   Chott, Andreas ^a   Müllauer, Leonhard ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; EXON; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; LARGE CELL LYMPHOMA; LIGAND BINDING; MISSENSE MUTATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; STOMACH LYMPHOMA;

EID: 10744223056     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63195-1     Document Type: Article

References (45)

1. Zucca E, Bertoni F, Roggero E, Cavalli F: The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000, 96:410-419
2. Du MQ, Isaacson PG: Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002, 3:97-104
3. Chan JK, Ng CS, Isaacson PG: Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol 1990, 136:1153-1164
4. Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U, Ott MM, Müller-Hermelink HK: The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant Non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997, 57:3944-3948
5. Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C: The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000, 156:1433-1439
6. Ye H, Liu H, Attygalle A, Wotherspoon AC, Nicholson AG, Charlotte F, Leblond V, Speight P, Goodlad J, Lavergne-Slove A, Martin-Subero JI, Siebert R, Dogan A, Isaacson PG, Du MQ: Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003, 102:1012-1018
7. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P: The apoptosis inhibitor gene API2 and a novel 18q gene MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609
8. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, Dixit VM: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one which plays a key role in MALT lymphoma. Mol Cell 2000, 6:961-970
9. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ, Isaacson PG: Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001, 357:39-40
10. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, Chott A: T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339
11. Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran L, Marin M, Blesa D, Horsman D, Rosenwald A, Staudt LM, Albertson DG, Du MQ, Ye H, Marynen P, Garcia-Conde J, Pinkel D, Dyer MJS, Martinez-Climent JA: MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101:4539-4546, 2003
12. Du M, Peng H, Singh N, Isaacson PG, Pan L: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995, 86:4587-4593
13. Wotherspoon AC, Pan LX, Diss TC, Isaacson PG: Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet 1992, 58:35-38
14. Du MQ, Peng H, Liu H, Hamoudi RA, Diss TC, Willis TG, Ye H, Dogan A, Wotherspoon AC, Dyer MJS, Isaacson PG: BCL10 gene mutation in lymphoma. Blood 95:3885-3890, 2000
15. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ: Bcl10 is involved in t(1;14)(p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96:35-45
16. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC: Tumor B cells from Non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998, 91:2875-2885
17. Seeberger H, Starostik P, Schwarz S, Knörr C, Kalla J, Ott G, Müller-Hermelink HK, Greiner A: Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest 2001, 81:977-986
18. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305
19. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169:1747-1756
20. Krammer PH: CD95's deadly mission in the immune system. Nature 2000, 407:789-795
21. Siegel RM, Chan FKM, Chun HJ, Lenardo MJ: The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nature Immunol 2000, 1:469-474
22. Takahashi Y, Ohta H, Takemori T: Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001, 14:181-192
23. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317
24. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946
25. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349
26. Gronbaek K, Straten P, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P: Somatic Fas mutations in Non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998, 92:3018-3024
27. Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa K: Frequent mutations of Fas gene in thyroid lymphoma. Cancer Res 2001, 61:1382-1385
28. Müschen M, Rajewsky K, Krönke M, Küppers R: The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 2002, 23:75-80
29. Radaszkiewicz T, Dragosics B, Bauer P: Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992, 102:1628-1638
30. Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001
31. Huang QR, Morris D, Manolios N: Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997, 34:577-582
32. Fiucci G, Ruberti G: Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogenetics 1994, 39:437-439
33. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB: The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999, 103:355-363
34. Itoh N, Nagata S: A novel protein domain required for apoptosis. J Biol Chem 1993, 268:10932-10937
35. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW: NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996, 384:638-641
36. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
37. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995, 11:294-300
38. Tighe PJ, Stevens SE, Dempsey S, Le Deist F, Rieux-Laucat F, Edgar JD: Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome. Genes Immun 2002, 3(Suppl 1):S66-S70
39. Bertoni F, Conconi A, Luminari S, Realini C, Roggero E, Baldini L, Carobbio S, Cavalli F, Neri A, Zucca E: Lack of CD95/Fas gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. Leukemia 2000, 14:446-448
40. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373:438-441
41. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM, Goodnow CC: CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995, 376:181-184
42. Morgner A, Miehlke S, Fischbach W, Schmitt W, Muller-Hermelink, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdorffer E: Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001, 19:2041-2048
43. Chen LT, Lin JT, Shyu RY, Jan CM, Chen CL, Chiang IP, Liu SM, Su IJ, Cheng AL: Prospective study of Helicobacter pylori eradication therapy in stage I (E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001, 19:4245-4251
44. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996, 2:574-577
45. Debatin KM: Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 2000, 112-113:41-48